NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Thursday, July 28, 2022. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Second Quarter … [Read more…]
DUBLINDUBLIN–(BUSINESS WIRE)–The “Femtech Market Research Report by Type (Products, Services, and Software), Application, End-use, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) – Global Forecast to 2027 – Cumulative Impact of COVID-19” report has been added to ResearchAndMarkets.com’s offering. The Global Femtech Market size was estimated at USD 24.99 billion in 2021 and expected … [Read more…]
CRYSVITA could offer access to the first biologic treatment for EU patients with TIO who cannot undergo surgical removal of tumours TOKYO–(BUSINESS WIRE)–Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended that CRYSVITA® (burosumab) be approved … [Read more…]
Innovaccer will participate as a member of the multisector alliance to advance healthcare data sharing, enabling consumers, patients, and caregivers easier access to health information SAN FRANCISCO–(BUSINESS WIRE)–Today, Innovaccer Inc., the Health Cloud company, announced that it has joined the CARIN Alliance (CARIN), a multisector collaborative working to rapidly advance the consumer-directed exchange of health … [Read more…]
HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)–$RDY #Acquisition–Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced that it has acquired a portfolio of branded and generic injectable products from Deer Park, Illinois based-Eton Pharmaceuticals, Inc. (NASDAQ: ETON). The portfolio includes the … [Read more…]
Company Filed a Definitive Information Statement Under Section 14C of the Exchange Act MELBOURNE, Australia–(BUSINESS WIRE)–Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that the Company filed a Definitive Information Statement under Section 14C of the Exchange … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Global Biosimilars Partnering Terms and Agreements 2010 to 2022” report has been added to ResearchAndMarkets.com’s offering. This report is intended to provide the reader with an in-depth understanding and access to Biosimilars trends and structure of deals entered into by leading companies worldwide. The report provides a detailed understanding and analysis of how … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Umbilical Cord Blood Processing Products Market Research Report by Product Type (CD Markers, Cell Culture Devices, and Cell Culture Reagents), End-Users, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) – Global Forecast to 2027 – Cumulative Impact of COVID-19” report has been added to ResearchAndMarkets.com’s offering. The Global Umbilical Cord Blood Processing … [Read more…]
Results of 100 subjects bridging study and 1,500 subjects placebo-controlled trial of Akston’s AKS-452 announced. Interim analysis shows a 91% seroconversion rate. Statistically-significant high antibody titers were maintained for six months in the bridging study. The vaccine was well tolerated, with no significant safety issues reported. AKS-452 is shelf-stable for over six months at room … [Read more…]
– Recommendation is Based on Week 26 Data from the CAPELLA Trial Showing Twice-Yearly Lenacapavir Achieved High Rates of Virologic Suppression in Heavily Treatment-Experienced People with HIV – – If Authorized, Lenacapavir Could Offer a New, Every Six-Month Treatment Option for People with Limited Treatment Choices – FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) … [Read more…]
